- Home
- ETON vs ESPR Comparison
ETON vs ESPR Comparison
Compare ETON & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- ESPR
- Stock Information
- Founded
- ETON 2017
- ESPR 2008
- Country
- ETON United States
- ESPR United States
- Employees
- ETON N/A
- ESPR N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- ESPR Health Care
- Exchange
- ETON Nasdaq
- ESPR Nasdaq
- Market Cap
- ETON 329.8M
- ESPR 305.0M
- IPO Year
- ETON 2018
- ESPR 2013
- Fundamental
- Price
- ETON $14.55
- ESPR $0.83
- Analyst Decision
- ETON Strong Buy
- ESPR Buy
- Analyst Count
- ETON 3
- ESPR 7
- Target Price
- ETON $27.67
- ESPR $6.07
- AVG Volume (30 Days)
- ETON 235.8K
- ESPR 5.6M
- Earning Date
- ETON 05-08-2025
- ESPR 05-06-2025
- Dividend Yield
- ETON N/A
- ESPR N/A
- EPS Growth
- ETON N/A
- ESPR N/A
- EPS
- ETON N/A
- ESPR N/A
- Revenue
- ETON $39,011,000.00
- ESPR $332,314,000.00
- Revenue This Year
- ETON $92.33
- ESPR $5.17
- Revenue Next Year
- ETON $52.62
- ESPR N/A
- P/E Ratio
- ETON N/A
- ESPR N/A
- Revenue Growth
- ETON 23.29
- ESPR 185.66
- 52 Week Low
- ETON $3.11
- ESPR $0.82
- 52 Week High
- ETON $18.41
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- ETON 57.21
- ESPR 20.11
- Support Level
- ETON $13.53
- ESPR $0.82
- Resistance Level
- ETON $14.40
- ESPR $1.06
- Average True Range (ATR)
- ETON 0.97
- ESPR 0.09
- MACD
- ETON 0.32
- ESPR -0.02
- Stochastic Oscillator
- ETON 96.19
- ESPR 5.57
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.